Does initial 45Gy of pelvic intensity-modulated radiotherapy reduce late complications in patients with locally advanced cervical cancer? A cohort control study using definitive chemoradiotherapy with high-dose rate brachytherapy

Chen, Shang-Wen; Liang, Ji-An; Yeh, Lian-Shung; Chang, Wei-Chun; Lin, Wu-Chou; Chien, Chun-Ru

doi:10.2478/raon-2013-0011

Abstract

Background. Comparing initial 45 Gy of pelvic intensity-modulated radiation therapy (IMRT) and non-IMRT in terms of the late toxicities associated with advanced cervical cancer that has also been treated with definitive concurrent chemoradiotherapy and high-dose rate intracavitary brachytherapy (HDRICB).

Patients and methods. This retrospective study included 320 stage IB2-IIIB cervical cancer patients treated with CCRT (83 IMRT and 237 non-IMRT). The two groups had similar stage and HDRICB ratings. Following 45 Gy to the pelvis, HDRICB of 24 Gy in four courses was prescribed. Late toxicities, including rectal complications (RC), bladder complications (BC) and non-rectal intestinal injury (NRRII), were scored by the Common Terminology Criteria for Adverse Events. A logistic regression was used to estimate the odds ratio (OR) of the complications.

Results. With a median follow-up duration of 33 and 77 months for IMRT and non-IMRT, 33 patients had Grade 2 or higher late RC (7.2% IMRT, 11.4% non-IMRT), whereas that for BC was 40 (9.6% IMRT, 13.5% non-IMRT) and for NRRII was 48 (12.0% IMRT, 16.0% non-IMRT). The cumulative rate for total grade 3 or higher gastrointestinal or genitourinary toxicities was 8.4% and 11.8% (p = 0.33). IMRT did not reduce the OR for all endpoints; however, the ORs for rectum and bladder reference doses to Point A were associated with RC and BC.

Conclusions. Locally advanced cervical cancer patients treated with initial 45Gy of pelvic IMRT and HDRICB have similar treatment-related late toxicities as those treated with non-IMRT. Optimization of the brachytherapy scheme is essential to minimize late toxicities.

References

1. Hasselle MD, Rose BS, Kochanski JD, Nath SK, Bafana R, Yashar CM, et al. Clinical outcome of intensity-modulated pelvic radiation therapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2011; 80: 1436-45.10.1016/j.ijrobp.2010.04.041
Search in Google Scholar
2. Kidd EA, Siegel BA, Dehdashti F, Rader JS, Mutic S, Mutch DG, et al. Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose- positron emission tomography simulation in patients with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2010; 77: 1085-91.10.1016/j.ijrobp.2009.06.041
Search in Google Scholar
3. Mundt AJ, Mell LK, Roeske JC. Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. Int J Radiat Oncol Biol Phys 2003; 56: 1354-60.10.1016/S0360-3016(03)00325-0
Search in Google Scholar
4. Ferrigno R, Santos A, Martins LC, Weltman E, Chen MJ, Sakuraba R, et al. Comparison of conformal and intensity modulated radiation therapy techniques for treatment of pelvic tumors. Analysis of acute toxicity. RadiatOncol 2010; 5: 117.
Search in Google Scholar
5. Brixey CJ, Roeske JC, Lujan AE, Yamada SD, Rotmensch J, Mundt AJ. Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 2002; 54: 1388-96.10.1016/S0360-3016(02)03801-4
Search in Google Scholar
6. Chen MF, Tseng CJ, Tseng CC, Kuo YC, Yu CY, Chen WC. Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy: Comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys 2007; 67: 1438-44.10.1016/j.ijrobp.2006.11.00517394944
Search in Google Scholar
7. Roeske JC, Bonta D, Mell LK, Lujan AE, Mundt AJ. A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensitymodulated whole-pelvic radiation therapy. Radiother Oncol 2003; 69: 201-7.10.1016/j.radonc.2003.05.00114643959
Search in Google Scholar
8. Mell LK, Kochanski JD, Roeske JC, Haslam JJ, Mehta N, Yamada SD, et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys 2006; 66: 1356-65.10.1016/j.ijrobp.2006.03.01816757127
Search in Google Scholar
9. Chen CC, Lin JC, Jan JS, Ho SC, Wang L. Definitive intensity-modulated radiation therapy with concurrent chemotherapy for patients with locally advanced cervical cancer. Gynecol Oncol 2011; 122: 9-13.10.1016/j.ygyno.2011.03.03421514629
Search in Google Scholar
10. Rogelj P, Hudej R, Petric P. Distance deviation measure of contouring variability. Radiol Oncol 2013; 47: 86-96.
Search in Google Scholar
11. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl JMed 1999; 340: 1154-61.10.1056/NEJM19990415340150310202166
Search in Google Scholar
12. Taylor A, Rockall AG, Reznek RH, Powell ME. Mapping pelvic lymph nodes: Guidelines for delineation in intensitymodulated radiotherapy. Int J RadiatOncol Biol Phys 2005; 63: 1604-12.10.1016/j.ijrobp.2005.05.06216198509
Search in Google Scholar
13. Lim K, Chan P, Dinniwell R, Fyles A, Haider M, Cho YB, et al. Cervical cancer regression measured using weekly magnetic resonance imaging during fractionated radiotherapy: Radiobiologic modeling and correlation with tumor hypoxia. Int J Radiat Oncol Biol Phys 2008; 70: 126-33.10.1016/j.ijrobp.2007.06.033
Search in Google Scholar
14. van de Bunt L, Jürgenliemk-Schulz IM, de Kort GA, Roesink JM, Tersteeg RJ, van der Heide UA. Motion and deformation of the target volumes during IMRT for cervical cancer: What margins do we need? Radiother Oncol 2008; 88: 233-40.
Search in Google Scholar
15. Chan P, Dinniwell R, Haider MA, Cho YB, Jaffray D, Lockwood G, et al. Interand intrafractional tumor and organ movement in patients with cervical cancer undergoing radiotherapy: A cinematic-MRI point-of interest study. Int J Radiat Oncol Biol Phys 2008; 70: 1507-15.10.1016/j.ijrobp.2007.08.055
Search in Google Scholar
16. Beadle BM, Jhingran A, Salehpour M, Sam M, Iyer RB, Eifel PJ. Cervix regression and motion during the course of external beam chemoradiation for cervical cancer. Int J Radiat Oncol Biol Phys 2009; 73: 235-41.10.1016/j.ijrobp.2008.03.064
Search in Google Scholar
17. Lim K, Small W, Portelance L, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiatherapy for the definitive treatment of cervix cancer. Int J Radiat Oncol Biol Phys 2011; 79: 348-55.10.1016/j.ijrobp.2009.10.075
Search in Google Scholar
18. Chen SW, Liang JA, Hung YC, Yeh LS, Chang WC, Lin WC, et al. Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: a control cohort comparison with radiation alone on treatment outcome and complications. Int J RadOncol Biol Phys 2006; 66: 1370-77.10.1016/j.ijrobp.2006.07.004
Search in Google Scholar
19. Chen SW, Liang JA, Hung YC, Yeh LS, Chang WC, Lin WC, et al. Geometrical sparing factors for the rectum and bladder in the prediction of grade 2 and higher complications following high-dose-rate brachytherapy for cervical cancer. Int J Rad Oncol Biol Phys 2009; 75: 1335-43.10.1016/j.ijrobp.2008.12.018
Search in Google Scholar
20. Chen SW, Liang JA, Yang SN, Hung YC, Yeh LS, Shiau AC, et al. Radiation injury to intestine following hysterectomy and adjuvant radiotherapy for cervical cancer. Gynecol Oncol 2004; 95: 208-14.10.1016/j.ygyno.2004.07.003
Search in Google Scholar
21. Eifel PJ, Levenback C, Wharton JT, Oswald MJ. Time course and incidence of late complications in patients treated with radiation therapy for FIGO Stage IB carcinoma of the uterine cervix. Int J Rad Oncol Biol Phys 1995; 32: 1289-300.10.1016/0360-3016(95)00118-I
Search in Google Scholar
22. Potter R, Haie-Meder C, Van Limbergen E, Barillot I, De Brabandere M, Dimopoulos J, et al. Recommendations from gynaecological GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervical cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 2006; 78: 67-77.10.1016/j.radonc.2005.11.01416403584
Search in Google Scholar
23. Ljuca D, Marosevic G. Quality of life in patients with cervical cancer FIGO IIb stage after concomitant chemoradiotherapy. Radiol Oncol 2009; 43: 293-8.10.2478/v10019-009-0025-9
Search in Google Scholar

Does initial 45Gy of pelvic intensity-modulated radiotherapy reduce late complications in patients with locally advanced cervical cancer? A cohort control study using definitive chemoradiotherapy with high-dose rate brachytherapy

Abstract

Paradigm

My account